Professor Jonathan Sprent
After a PhD at the Walter Eliza Hall Institute in Melbourne and post-doctoral positions in Switzerland and UK, Professor Jonathan Sprent worked for 30 years in the USA, first at the University of Pennsylvania in Philadelphia and then at The Scripps Research Institute in San Diego. During this time he worked on many aspects of T cell biology, including T-B collaboration during antibody production, role of T cells in graft-versus host disease after bone marrow transplantation, positive and negative selection during T cell differentiation in the thymus, T cell survival and homeostasis of mature T cells, construction of artificial antigen-presenting cells (APC) from insect cells, and the use of monoclonal antibodies (mAb) to enhance and target the activity of IL-2 and other cytokines. Jonathan moved from the USA in 2006 to form a research group at the Garvan Institute of Medical Research where he has continued to work on T cell differentiation and function. The lab is supported by several NHMRC grants and has collaborative interactions with many other investigators, both nationally and internationally.
- 1998President of the American Association of Immunologists
- 2023International journal of molecular sciences10.3390/ijms24021752
Treg Therapy for the Induction of Immune Tolerance in Transplantation-Not Lost in Translation?
The retroelement Lx9 puts a brake on the immune response to virus infection.
- 2022Frontiers in immunology10.3389/fimmu.2022.959115
Editorial: Immunological Tolerance in Transplantation: More Than Deletion.
- 2022Frontiers in immunology10.3389/fimmu.2022.870542
Redefining the Foreign Antigen and Self-Driven Memory CD4 T-Cell Compartments Transcriptomic, Phenotypic, and Functional Analyses.
- 2021Frontiers in immunology10.3389/fimmu.2021.801595
Impact of Graft-Resident Leucocytes on Treg Mediated Skin Graft Survival.